Company Executives

$OVID Management Team

Dr. Jeremy Levin

Executive Chairman of the Board

Age 72

Compensation $2.774M USD

Sex Male

Mr. Jeffrey Rona

Chief Business and Financial Officer

Age 56

Compensation $1.519M USD

Sex Male

Ms. Margaret Alexander

President

Chief Executive Officer

Director

Age 44

Compensation $1.655M USD

Sex Female

Name / Title	Age	Compensation	Sex
Dr. Jeremy Levin Executive Chairman of the Board	72	$2.774M USD	Male
Mr. Jeffrey Rona Chief Business and Financial Officer	56	$1.519M USD	Male
Ms. Margaret Alexander President Chief Executive Officer Director	44	$1.655M USD	Female

Board of Directors

From the proxy statement filed Apr 27, 2026

Directors

serving now

Independent

0 of 2

stated in the proxy; 5 not stated

Average tenure

5.2 years

from year joined

CEO also chairs the board

Levin

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Barbara Duncan	61	2017 9 years	Not stated	Nominating and Corporate Governance	Halozyme Therapeutics, Inc., Atea Pharmaceuticals, Inc., Fusion Pharmaceuticals Inc.	$86,266
Stelios Papadopoulos	77	2025 1 year	Not stated	Audit Compensation	Exelixis, Inc.	$88,906
Margaret Alexander CEO	45	2026 0 years	Not independent	None stated	None stated	Paid as CEO
Bart Friedman Lead independent director	81	2015 11 years	Not stated	Audit	None stated	Not stated
Kevin Fitzgerald	58	2021 5 years	Not stated	Nominating and Corporate Governance	None stated	$69,940
Karen Bernstein	Not stated	Not stated	Not stated	None stated	None stated	$89,940
Levin Board chair	Not stated	Not stated	Not independent	None stated	None stated	Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 27, 2026

Jeremy M. Levin, DPhil, MB BChir

99,400

Purchased Common Stock and Warrants in the 2025 private placement (2025 PIPE financing)

Open in proxy

RA Capital Healthcare Fund, L.P.

14,999,600

Purchased Common Stock and Warrants in the 2025 private placement (2025 PIPE financing)

Open in proxy

Point72 Associates, LLC

24,994,161

Purchased Common Stock and Pre-Funded Warrants in the 2026 private placement (2026 PIPE)

Open in proxy

Comments

Company Executives

$OVID Management Team

Dr. Jeremy Levin

Mr. Jeffrey Rona

Ms. Margaret Alexander

Board of Directors

Related-party transactions